These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
162 related items for PubMed ID: 20496145
1. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. Tapaninen T, Neuvonen PJ, Niemi M. Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145 [Abstract] [Full Text] [Related]
6. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M. Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832 [Abstract] [Full Text] [Related]
8. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Vaidyanathan S, Maboudian M, Warren V, Yeh CM, Dieterich HA, Howard D, Dole WP. Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303 [Abstract] [Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clin Pharmacokinet; 2008 Aug; 47(8):515-31. PubMed ID: 18611061 [Abstract] [Full Text] [Related]
11. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin Dieterich H. Clin Pharmacokinet; 2006 Aug; 45(11):1125-34. PubMed ID: 17048976 [Abstract] [Full Text] [Related]
15. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, Kim IW, Jones A, Arora M, Gribar J, Gurwitz D, Gottesman MM. Pharmacogenomics; 2007 Jan; 8(1):29-39. PubMed ID: 17187507 [Abstract] [Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Buczko W, Hermanowicz JM. Pharmacol Rep; 2008 Jan; 60(5):623-31. PubMed ID: 19066408 [Abstract] [Full Text] [Related]
17. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study. Hu P, Bartlett M, Karan RS, Jiang J, Zhang S, Zhang J, Howard D, Yeh CM, Al-Fayoumi S, Jarugula V, Dole WP. Clin Drug Investig; 2010 Jan; 30(4):221-8. PubMed ID: 20192280 [Abstract] [Full Text] [Related]
18. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Magliulo L, Dahl ML, Lombardi G, Fallarini S, Villa LM, Biolcati A, Scordo MG. Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330 [Abstract] [Full Text] [Related]
19. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA. Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853 [Abstract] [Full Text] [Related]
20. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Ayalasomayajula S, Tchaloyan S, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150 [Abstract] [Full Text] [Related] Page: [Next] [New Search]